- 18 Apr 2018 Kymab presents data on two of its immuno-oncology antibodies, providing further evidence of the strength of its franchise
- 12 Jan 2018 Kymab ‘top European biotech to watch’ in 2018
- 4 Dec 2017 Anti-PD-L1 antibody KY1003 shows anti-tumour efficacy
- 8 Nov 2017 KY1044 strongly inhibits tumour growth in models
- 21 Sep 2017 KY1005 impressive in acute GVHD model
- 31 Jul 2017 Kymab's KY1005 antibody in clinical trial
- 23 Jan 2017 Arndt Schottelius appointed Executive VP R&D
- 9 Jan 2017 Kymab expands Infectious Disease Programmes
- 5 Dec 2016 Antibody shows dramatic post-transplant benefit
- 11 Oct 2016 Bispecific antibody agreement with EpimAb
We use cookies on our website. Carry on browsing if you’re happy with this or find out more
Featured article: Forbes on Kymab: exciting the big guys
Forbes magazine recognises Kymab's work is 'exciting the big and little guys' and places the company in a select group of UK 'Unicorns'
Read article
Featured article: Promising First Clinical Study of KY1005 for immune-mediated diseases
Positive data in Phase I trial of KY1005 will lead to Phase II studies in atopic dermatitis, with additional plans to run studies in othe...
Read article